FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology and immunology. Described are various variants of anti-IL-1R1 antibodies. The disclosed antibodies can be applicable for treating IL-1R1-mediated disorders, including rheumatoid arthritis, asthma, and chronic obstructive pulmonary disease (COPD).
EFFECT: presented group of inventions can be used in medicine.
21 cl, 14 dwg, 12 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS | 2007 |
|
RU2466139C2 |
| ANTIBODY AGAINST IL-4R AND APPLICATION THEREOF | 2018 |
|
RU2758091C1 |
| GM-CSF RECEPTOR BINDER | 2007 |
|
RU2495050C2 |
| ELEMENT BOUND WITH INTERLEUKIN-4 RECEPTOR α (IL-4Rα)-173 | 2008 |
|
RU2490278C2 |
| NEUTRALIZING BINDING MOLECULES DIRECTED AGAINST INFLUENZA VIRUS, AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2721706C2 |
| HUMAN IL-13 ANTIBODY MOLECULES | 2004 |
|
RU2387667C2 |
| ISOLATED ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT SPECIFIC FOR HUMAN IMMUNOGLOBULIN E (VERSIONS), NUCLEIC ACID MOLECULE CODING IT, HOST CELL, METHOD FOR PREPARING ANTIBODY OR ITS ANTIGEN-BINDONG FRAGMENT, PHARMACEUTICAL COMPOSITION, USE THEREOF FOR TREATING IgE-ASSOCIATED DISEASES | 2008 |
|
RU2466140C2 |
| ANTIBODIES TO CD70 | 2012 |
|
RU2604196C2 |
| ANTIBODIES SPECIFIC TO BTN2 AND THEIR APPLICATIONS | 2018 |
|
RU2794996C2 |
| HUMAN RET-BINDING ANTIBODIES AND METHODS OF USE THEREOF | 2020 |
|
RU2821548C2 |
